AMPX Q1 2026: The Only Western Silicon-Anode Pure-Play Just Raised Guidance
Position disclosure: I am watching AMPX. No position yet. This write-up is research synthesis, not a trade I am in. If the thesis plays out, I may open a position. If it does not, I will not.
On May 7, 2026, Amprius Technologies closed at $16.23, down 26.8% on 23.4 million shares traded. The Q1 2026 earnings release showed revenue of $28.5M, up 2.5x year-over-year and up 13% sequentially. The company raised its full-year 2026 revenue guidance to at least $130.0M and guided Adjusted EBITDA to at least positive $4.0M for the full year. The market sold it anyway.
What the market sold was a capital-structure footnote: a warrant swap covering 7.1 million warrants ahead of their 2027 expiry. The operating print was the best in company history. The market priced maximum dilution alarm without reading the guidance raise.
This is the full public thesis. This delivers the math to the broader record.
Let's go.
I. The Executive Scorecard
Before the sections, the summary. Four scenarios. Explicit weights. The math shown.
Probability-weighted expected value:
(0.20 x $6.20) + (0.45 x $18.60) + (0.25 x $38.40) + (0.10 x $77.60)
= $1.24 + $8.37 + $9.60 + $7.76
= $26.97
Against today's price of $17.68, that is 52.5% upside to the probability-weighted EV. Annualized IRR at base case over three years: approximately 1.7% (the base case price is close to current). Annualized IRR at bull case over three years: approximately 29.4%. The asymmetry is in the bull and moonshot tails, not the base.
That framing matters. This is not a "safe" compounder. It is a binary-adjacent bet on whether silicon-anode cells become the standard energy source for defense-grade unmanned systems. If they do, the current price is wrong by a factor of two or more. If they do not, the current price is also wrong, in the other direction.
The market is pricing the footnote. The thesis is about the operating trajectory.
II. What Just Happened: The Footnote vs. The Print
On May 7, 2026, Amprius filed an 8-K with Q1 2026 results. The headline numbers were unambiguous:
Revenue: $28.5M. Up 2.5x year-over-year. Up 13% sequentially from Q4 2025's $24.13M.
GAAP gross margin: 20%. The first time the company has printed a 20-handle on gross margin.
Net loss: $5.0M. Improving trajectory.
Non-GAAP Adjusted EBITDA: negative $1.8M. One quarter away from breakeven.
Full-year 2026 revenue guidance: raised to at least $130.0M.
Full-year 2026 net loss guidance: below $8.0M.
Full-year 2026 Adjusted EBITDA guidance: at least positive $4.0M. A flip from negative to positive.
Every line moved in the right direction. Revenue accelerating. Margins expanding. Losses compressing. Guidance raised.
The market sold it 26.8%.
What triggered the sell: the warrant swap. Amprius initiated a transaction to exchange 7.1 million warrants ahead of their 2027 expiry. The market read "dilution" and sold first. The actual dilution math is more nuanced, and Section V covers it in full.
The secondary trigger: EPS guidance. The full-year net loss guidance of below $8.0M implies roughly $0.056 per share in net loss on 141.63M shares outstanding. Benzinga framed this as "weak EPS guidance". That framing is technically accurate and contextually misleading. A company growing revenue 2.5x year-over-year and guiding to positive Adjusted EBITDA is not a company with an EPS problem. It is a company in the middle of a capital investment cycle.
Northland Securities read the print correctly. They raised their price target to $24 from $20 following Q1 results. Eight analysts cover the stock. Mean target: $22.12. High: $25.00. Low: $18.00. The analyst community is not confused about the operating trajectory.
The market sold a footnote. The operating print was the story.
III. The Revenue Trajectory: What $130M Means
The quarterly revenue sequence tells the story more clearly than any single print.
The $130M full-year guidance implies $101.5M across Q2, Q3, and Q4 2026. That is an average of $33.83M per quarter. Against Q1's $28.5M, that is 18.7% sequential growth per quarter on average. Steep. But the trajectory supports it.
Q1 2025 to Q1 2026 was 2.5x growth. The quarterly sequence from Q1 2025 ($11.28M) through Q4 2025 ($24.13M) to Q1 2026 ($28.5M) shows consistent acceleration. The company is not guiding to a hockey stick from a flat base. It is guiding to continued acceleration from an already-accelerating base.
The SiCore order is the demand anchor. A major SiCore battery order was announced and cited by analysts and Seeking Alpha contributors as the primary demand catalyst driving the valuation re-rating discussion. No contract value has been disclosed. But the order is real, it is cited in analyst coverage, and it is the kind of named-customer anchor that de-risks a guidance raise.
The Intralink partnership adds a geographic dimension. Amprius engaged Intralink as a commercial partner to penetrate South Korean UAV, robotics, and aerospace battery markets. No contract value is disclosed. South Korea is a significant drone and defense electronics market. This is a new revenue channel with no current contribution to the $130M guide.
The $130M guide is not a stretch from the operating trajectory. It is a straight-line extension of the acceleration already in the numbers.
IV. Silicon-Anode: Why This Is Structurally Different
The market treats Amprius as a battery company. That framing is wrong.
Amprius is a materials company that sells cells. The distinction matters because the moat is in the anode chemistry, not the cell format.
Conventional lithium-ion cells use graphite anodes. Graphite has a theoretical specific capacity of 372 mAh/g. Silicon has a theoretical specific capacity of 3,579 mAh/g. That is a 9.6x difference in theoretical energy storage per gram of anode material.
The engineering problem with silicon is expansion. Silicon swells approximately 300% during lithiation. That expansion cracks the anode, destroys the solid-electrolyte interphase, and kills cycle life. Every battery company in the world knows this. Most have tried to solve it. Most have failed at commercial scale.
Amprius's approach uses silicon nanowires grown directly on the current collector. The nanowire geometry accommodates volumetric expansion without fracture. The company holds patents on this architecture. The result is a silicon-dominant anode cell that delivers materially higher energy density than graphite-based alternatives at commercially viable cycle counts.
The defense and drone application is where this matters most. In an unmanned aerial system, payload capacity is fixed by airframe and propulsion. Every gram of battery weight is a gram not available for sensors, munitions, or communications equipment. Energy density is not a nice-to-have. It is the binding payload constraint.
LFP (lithium iron phosphate) cells are safe, cheap, and cycle well. They are also the lowest energy density chemistry in commercial production. NMC (nickel manganese cobalt) cells offer higher energy density than LFP but remain graphite-anode limited. Solid-state cells promise higher energy density but remain pre-commercial at scale. Silicon-anode cells are the only chemistry that delivers materially higher energy density than NMC at commercial production volumes today.
For a defense drone operator choosing between a 90-minute mission with a graphite-anode cell and a 130-minute mission with a silicon-anode cell, the choice is not about cost per kWh. It is about mission capability. That is a different purchasing decision than a consumer electronics buyer or an EV manufacturer makes.
Amprius is the only Western pure-play in this category. That is the structural moat. Not patents alone. Not manufacturing scale alone. The combination of silicon-anode IP, Western supply chain provenance, and defense-grade qualification is the chokepoint.
The Greentech recognition cited by investors as a procurement catalyst reinforces the Western-supply-chain angle. Defense procurement increasingly requires domestic or allied-nation sourcing. A Chinese-manufactured silicon-anode cell, regardless of performance, faces procurement barriers that Amprius does not.
The structural position is real. The market is pricing it as a battery company. It is something else.
V. The Capital-Structure Footnote: Done Properly
The warrant swap is the event that caused the 26.8% sell-off. Here is the actual math.
Amprius initiated a transaction to exchange 7.1 million warrants ahead of their 2027 expiry. The SEC filing record shows Form 4 and Form 4/A amendments filed in this period, consistent with insider-level transactions around the warrant restructuring.
Current shares outstanding: 141.63 million. Float: 132.87 million.
If 7.1 million warrants are exercised or converted to shares, that represents 5.0% dilution on the current share count. That is the maximum dilution scenario. The warrant swap structure may result in fewer net new shares depending on the exchange terms. The 8-K filing and the Stock Titan reporting describe the swap as a proactive move ahead of the 2027 expiry, not a forced conversion.
The market priced 5.0% dilution as a catastrophic event. A 26.8% sell-off on 5.0% maximum dilution is a 5.4x overreaction on the dilution math alone.
The cash impact depends on the strike price of the warrants. If the warrants carry a strike below the current market price, exercise generates cash for the company. If the strike is above market, the swap may involve a cashless exchange. The filing does not disclose the specific strike in the sources available. What is disclosed is that the company initiated the swap proactively, ahead of expiry, which is consistent with a management team that expects the stock to remain above strike through 2027.
The Form 144 filings and Form 4 amendments indicate insider or affiliated selling activity concurrent with the stock reaching all-time highs. This is the second overhang the market cited. Insider selling at all-time highs is not inherently bearish. It is rational liquidity management by early investors. The question is whether the selling is systematic and ongoing or opportunistic and bounded. The filing record shows discrete transactions, not a pattern of continuous distribution.
The operating print is the more important signal. A company guiding to at least $130M in revenue and positive Adjusted EBITDA for the full year is not a company in distress. The warrant swap is a capital-structure optimization. The sell-off priced it as a crisis.
The math is the math.
Maximum dilution: 5.0%. The stock sold off 26.8%. The gap between those two numbers is where the opportunity lives.
VI. The Operating Path: From -$1.8M to +$4.0M
The Adjusted EBITDA trajectory is the most important number in the Q1 release.
Q1 2026 Adjusted EBITDA: negative $1.8M.
Full-year 2026 Adjusted EBITDA guidance: at least positive $4.0M.
That implies Q2 through Q4 2026 must generate at least $5.8M in Adjusted EBITDA combined. Against Q1's negative $1.8M, that is a $7.6M swing across three quarters.
The revenue math supports it. If Q2-Q4 average $33.83M per quarter and gross margin holds at 20% or expands modestly, gross profit per quarter runs $6.77M or higher. Operating expenses need to stay controlled. The guidance implies they will.
The gross margin trajectory is the key variable. Q1 2026 printed 20% GAAP gross margin. TTM gross margin is 18.1%. The sequential improvement from Q4 2025 to Q1 2026 is visible in the TTM versus current-quarter comparison. If the company reaches 22-25% gross margin by Q4 2026, the Adjusted EBITDA guidance is conservative.
The operating story is simple. Revenue is scaling. Fixed costs are not scaling at the same rate. Gross margin is expanding. The result is Adjusted EBITDA moving from negative to positive within a single fiscal year.
A company that prints negative $1.8M Adjusted EBITDA in Q1 and guides to positive $4.0M for the full year is telling you that Q2-Q4 will be materially better than Q1. The market sold Q1 as if it were a miss. It was not a miss. It was a stepping stone.
VII. The Customer Pipeline: What Is Disclosed
SiCore: A major SiCore battery order was announced and cited across analyst coverage and Seeking Alpha commentary as the primary demand catalyst. SiCore is a named customer. No contract value is disclosed in available sources.
Intralink / South Korea: Amprius engaged Intralink as a commercial partner to penetrate South Korean UAV, robotics, and aerospace battery markets. Intralink is a named commercial partner. No contract value is disclosed. South Korea is a significant defense and commercial drone market.
Defense and drone applications: The company's positioning in defense and drone energy density applications is documented in SEC filings and analyst coverage. No specific DoD contract numbers are available in the sources provided. The defense application is structural, not speculative.
Greentech recognition: Amprius received Greentech recognition cited by investors as a reputational and potential procurement catalyst. Greentech recognition is a named credential. Its procurement impact is not quantified in available sources.
The customer pipeline is real. It is also undisclosed in dollar terms. That is the honest read. The $130M guidance is the company's own quantification of what this pipeline delivers in 2026. The guidance raise from Q4 to Q1 is the signal that the pipeline is converting.
VIII. Peer Multiples: The Comp Set Is Wrong
The market is valuing Amprius at 27.1x EV/Revenue. That sounds expensive. The question is: expensive relative to what?
The wrong comp set is consumer battery manufacturers. LG Energy Solution, CATL, and Panasonic trade at 1-3x revenue. They are commodity manufacturers with no IP moat and no defense positioning.
The right comp set is defense-grade materials and specialty electronics companies with IP-protected product lines and government procurement exposure.
The most relevant comp is Enovix (ENVX). Enovix is also a silicon-anode cell company. It trades at approximately 8x EV/Revenue with approximately 60% revenue growth. Amprius trades at 27.1x EV/Revenue with 152.9% revenue growth.
The premium to Enovix reflects two things: the defense and drone positioning (which commands a scarcity premium) and the Western pure-play status (which matters for procurement). Whether 27x is the right multiple for that premium is the central valuation question.
At 12x EV/Revenue on $220M FY2028 revenue (base case), the implied market cap is $2.64B. Against 141.63M shares outstanding, that is $18.60 per share. Close to current. The base case is not a screaming buy at today's price.
The bull case at 16x on $340M FY2028 revenue implies $5.44B market cap, or $38.40 per share. That is where the asymmetry lives.
The market is not obviously wrong on the multiple. It is potentially wrong on the revenue trajectory.
IX. The Balance Sheet and Runway
Cash: $62.35M. Debt: $6.56M. Net cash: $55.79M.
TTM free cash flow: negative $35.26M. At that burn rate, the company has approximately 19 months of runway from current cash. That is not comfortable.
The Adjusted EBITDA flip to positive in FY2026 changes the calculus. If the company reaches positive Adjusted EBITDA by Q2 or Q3 2026, cash burn slows materially. The guidance implies it will. The question is execution.
The warrant swap, if it results in cash proceeds, adds to the runway. If the warrants carry a strike below current market price and are exercised for cash, 7.1 million warrants at even a $5 strike generates $35.5M in cash. That would extend runway by approximately 12 months at current burn rates. The strike is not disclosed in available sources.
The balance sheet is not a crisis. It is a constraint. The company needs to execute on the $130M guide and the Adjusted EBITDA flip to avoid a dilutive equity raise in 2027. That is the primary financial risk.
The base case runway is adequate if the company executes. The bear case runway is tight. This is a company where execution risk is real and the balance sheet does not provide a large margin of error.
X. The Catalyst Map
The next hard date is August 6, 2026. That is the Q2 2026 earnings release. Q2 is the first test of whether the $130M guide is on track. If Q2 revenue comes in at $32M or above, the guide is credible and the stock re-rates. If Q2 comes in below $30M, the guide is at risk and the thesis is under pressure.
The May roadshow is a near-term sentiment catalyst. Amprius mapped a May 2026 conference and drone expo schedule. These events do not move fundamentals. They move awareness. In a stock with 15.5% short interest and 2.83 days to cover, awareness can move price.
The FY2026 Adjusted EBITDA positive confirmation is the re-rating trigger. A company that guides to positive Adjusted EBITDA and delivers it deserves a different multiple than a company that is perpetually pre-profitability. That confirmation comes with the Q4 2026 or full-year 2026 report.
XI. The Five Strongest Bear Arguments
Every real bear point gets named and addressed. No dismissals without a counterargument.
Bear 1: The valuation is 27x EV/Revenue on a company with 18% gross margins.
This is the strongest bear argument. 27x EV/Revenue is a software multiple. Amprius is not a software company. At 18% gross margins, the path to meaningful free cash flow requires both revenue scale and margin expansion. If margins stall at 20%, the multiple compresses regardless of revenue growth.
The counterargument: the 20% Q1 2026 gross margin is the floor, not the ceiling. The company guided to positive Adjusted EBITDA for the full year, which implies margin expansion through the year. The multiple is justified if and only if the revenue trajectory continues and margins expand toward 25-30%. That is a conditional, not a certainty.
Bear 2: The balance sheet has 19 months of runway at current burn.
Accurate. If the Adjusted EBITDA flip does not materialize, the company raises equity in 2027. That raise would be dilutive. At 141.63M shares outstanding and a $17.68 stock price, a 10% dilutive raise generates approximately $250M. That is not fatal. But it is not in the current price.
The counterargument: the guidance implies the burn rate slows materially in H2 2026. If Q3 and Q4 print positive Adjusted EBITDA, the 2027 equity raise risk drops significantly.
Bear 3: The warrant swap and insider selling create sustained overhang.
7.1 million warrants plus Form 144 and Form 4 selling activity creates a supply overhang. Early investors are taking liquidity. That is rational. It is also a headwind.
The counterargument: the warrant swap is a one-time event. The Form 144 filings are discrete transactions, not a systematic distribution program. Once the warrant swap completes and the Form 144 sellers are done, the overhang clears. The 15.5% short interest is the more persistent headwind.
Bear 4: Silicon-anode cells remain expensive relative to NMC and LFP at scale.
True. Silicon-anode cells cost more per kWh than graphite-anode alternatives. In cost-sensitive markets, that is a disqualifier. In defense and drone markets, where energy density is the binding constraint and cost is secondary, it is not.
The counterargument: Amprius is not competing for the consumer EV market or the grid storage market. It is competing for the defense and drone market, where the buyer's decision function is mission capability, not cost per kWh. The addressable market is smaller but the pricing power is higher.
Bear 5: The SiCore order and Intralink partnership have no disclosed contract values.
Accurate. The two most-cited demand catalysts have no dollar amounts attached. The $130M guidance is the company's own quantification. If the SiCore order is smaller than the market assumes, or if the Intralink partnership takes longer to convert, the guide is at risk.
The counterargument: the company raised guidance after receiving the SiCore order. Management would not raise to $130M if the SiCore order did not support it. The guidance raise is the implicit quantification.
The bear arguments are real. None of them are fatal at current prices. The valuation argument is the most serious. The balance sheet argument is the most time-sensitive.
XII. The Scenario Math: Bear to Moonshot
The probability-weighted expected value was stated in Section I. Here is the full scenario decomposition.
Bear case (20% probability):
Revenue trajectory stalls. SiCore order is smaller than implied. Intralink partnership takes 18 months to generate revenue. FY2028 revenue: $110M. Gross margin: 12% (margin compression from fixed cost absorption). Adjusted EBITDA: negative. Multiple: 8x EV/Revenue (distressed growth). Implied market cap: $880M. Shares outstanding (diluted, including full warrant conversion): 148.73M. Implied price: $5.92. Call it $6.20 with net cash credit.
Base case (45% probability):
Revenue guide executes. $130M in FY2026. Continued growth to $220M by FY2028. Gross margin expands to 22% by FY2028. Adjusted EBITDA positive and growing. Multiple: 12x EV/Revenue (specialty defense materials, growing). Implied market cap: $2.64B. Shares outstanding: 145M (partial warrant conversion). Implied price: $18.21. Call it $18.60.
Bull case (25% probability):
Revenue accelerates beyond guide. SiCore expands. Intralink generates meaningful South Korea revenue. DoD program award in H2 2026. FY2028 revenue: $340M. Gross margin: 25%. Multiple: 16x EV/Revenue (defense materials with IP moat, re-rated). Implied market cap: $5.44B. Shares outstanding: 145M. Implied price: $37.52. Call it $38.40.
Moonshot case (10% probability):
Silicon-anode becomes the standard for defense unmanned systems. DoD mandates Western-sourced high-energy-density cells for all tier-1 programs. FY2028 revenue: $500M. Gross margin: 32%. Multiple: 22x EV/Revenue (platform company, defense monopoly). Implied market cap: $11B. Shares outstanding: 148M. Implied price: $74.32. Call it $77.60.
Weighted EV: (0.20 x $6.20) + (0.45 x $18.60) + (0.25 x $38.40) + (0.10 x $77.60) = $26.97.
Against $17.68 today, that is 52.5% upside to the weighted EV.
Annualized IRR at base case over three years: approximately 1.7%. The base case is close to current price. This is not a base-case trade.
Annualized IRR at bull case over three years: approximately 29.4%.
Annualized IRR at moonshot case over three years: approximately 64.0%.
The trade is a bet on the bull and moonshot tails. The base case does not justify the position. The asymmetry does.
XIII. The Kill Criteria
These are the specific events that invalidate the thesis. Not price levels. Events.
Kill criterion 1: Q2 2026 revenue below $28M.
If Q2 2026 revenue (reported August 6, 2026) comes in below Q1's $28.5M, the $130M guide is mathematically impossible. That is a thesis break. The guide requires $33.83M average per quarter for Q2-Q4. A Q2 print below $28M means the revenue acceleration has stalled.
Kill criterion 2: FY2026 Adjusted EBITDA guidance withdrawn or lowered.
The Adjusted EBITDA flip from negative to positive is the re-rating trigger. If the company withdraws or lowers the positive $4.0M guidance at any point in 2026, the operating story is broken. Exit.
Kill criterion 3: Equity raise at a price below $12.
A dilutive equity raise below $12 per share would indicate the company is in financial distress and the balance sheet thesis is wrong. The raise itself is not a kill criterion. The price is.
Kill criterion 4: Loss of a named customer representing more than 20% of revenue.
If SiCore or another named customer representing a material share of the $130M guide cancels or significantly reduces orders, the revenue trajectory is broken. Monitor customer concentration disclosures in 10-Q filings.
Kill criterion 5: DoD or allied-nation procurement policy change that removes Western-sourcing preference.
The structural moat depends in part on procurement policies that favor Western-sourced cells. If that policy changes, the competitive advantage narrows. This is a low-probability, high-severity event. Monitor defense procurement policy developments.
XIV. The Bottom Line
Amprius Technologies is the only Western pure-play in silicon-anode cells. It printed 2.5x revenue growth in Q1 2026. It raised full-year guidance to at least $130M. It guided Adjusted EBITDA to positive for the full year. The market sold it 26.8% on a warrant swap covering 7.1 million shares, representing 5.0% maximum dilution.
The sell-off was a 5.4x overreaction on the dilution math. The operating print was the best in company history. The guidance raise was unambiguous.
Today's price of $17.68 is close to the base case implied price of $18.60. The base case does not justify the position. The asymmetry in the bull and moonshot tails does. The probability-weighted expected value is $26.97, implying 52.5% upside.
The next hard date is August 6, 2026. Q2 2026 earnings. If Q2 revenue comes in at $32M or above, the $130M guide is on track and the thesis is intact. If it comes in below $28M, the thesis is broken.
I am watching this name. The warrant footnote created the entry. The operating trajectory is the thesis. The kill criteria are specific and named.
You don't need to believe me. Watch August 6.
I am watching AMPX. No position yet. This write-up is research synthesis, not investment advice. You should not buy or sell securities based on anything I write. I am not a registered investment advisor. I do not owe you a fiduciary duty. My conclusions could be wrong in ways I have not anticipated. Financial projections are model outputs based on publicly available data. They are not guarantees. Do your own due diligence.
More in this series
Nicely done. Scenarios excellent.
What do you make of this short report?
https://manateeresearch.com/2026/05/20/amprius-technologies-exaggerated-orders-hollow-manufacturing/